Foscarbidopa

DB16171ApprovedSmall molecule

Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Parkinson's...

Chemical structure of Foscarbidopa
Mechanism
Curator reviewed
Formula / weight
C10H15N2O7P · 306.211 g/mol (avg)
First approval
Canada, 2023 · United States, 2022

Resolves to

Compound
UNII5NT8HCA4OOCAS1907685-81-7ChEMBLCHEMBL4802240ChEBI192511
Clinical / RWD
RxNorm2695774
Structure
InChIKeyPQUZXFMHVSMUNG-JTQLQIEISA-NSMILESC[C@@](CC1=CC=C(OP(O)(O)=O)C(O)=C1)(NN)C(O)=O
Targets
P20711DDC

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Marketed productsAcross 3 countries and 1 labeller
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Foscarbidopa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In